JAKi and TYK2i: What/when to use? You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. It is difficult to know which to choose https://t.co/uid38oFBXP https://t.co/gLJfJNi2Jh

Swedish national cohort study cohort study suggests #RA pts at incr risk for Autoimmune thyroid Dz, but decreases after RA Dx & Rx. n=13,731 RA vs 63,201 matched pop. controls. Lower rates AITD w/ biologics & TNFi (HR 0.54, 0.67) https://t.co/ZfputgDJQE https://t.co/Z1r0eGFcX9

Last chance for early bird savings! Our early bird special closes on 11/30. Join us for RheumNow Live THIS JANUARY! https://t.co/uD01S8rgrh https://t.co/29u3wz5PHK

National pharmacovigilance database review (1992 to 2021) identified 2217 "Falls", most serious, most in women (61%), & 38% in 18–64 yr olds. Falls attributed to immunomodulators (17%), 24% Fxs & 1 in 7 classified as adverse drug rxns (343) https://t.co/tpUPDc8x09 https://t.co/jdssH7oCjF

UK study 336 GCA pts shows after 12 mos of tocilizumab, TCZ stopped (w mean pred 2mg/d) & GCA flares at 6, 12 & 24 mos was 21%, 35% & 49% respectively; requiring prednisolone dose increase to 20 (10-40) mg/day (34% were major relapses) https://t.co/EZ78ciNK0R https://t.co/R1qFsvnhoF

"Protein kinases: drug targets for immunological disorders". Great full-read review from J Shea et al. Reviews Hx, biology, clinical use and safetey of Kinase targeted therapy. https://t.co/qBc0ng1Z9h https://t.co/Qm8PFpNxQF

NEJM Clinical Images: Scleromyxedema (cutaneous mucinosis w/ a paraproteinemia).53-yoM w/ itchy rash, Raynauds, dysphagia, burning dysesthesia hands; Waxy papules across forehead & hands w/ skin thickening & finger contractures. Skin Bx & SPEP done https://t.co/vkpYGNd3Uw https://t.co/T5gVPRBrhh

Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/iWnBTqX1eV https://t.co/lDEyM0c2yo

How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/jHrA1M05Qr https://t.co/jcU13Y4CRm

Effective Treatments for Rheumatoid Arthritis ILD The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence. https://t.co/qJBeM0jdom https://t.co/vdhcHOvHBI

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/uhlnpmLwoP https://t.co/NRW0PlD43a

Undiagnosed IBD in AxSpA Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Convergence meeting in San Diego. https://t.co/QAC6fhSQ7Q https://t.co/BxNQwQ9nwc